At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01875 BIODLINK-B
Trading 08-20 15:38:02
4.000
+0.090
+2.30%
High4.145
Low3.960
Vol1.35M
Open3.960
D1 Closing3.910
Amplitude4.73%
Mkt Cap3.09B
Tradable Cap3.09B
Total Shares773.00M
T/O5.48M
T/O Rate0.17%
Tradable Shares772.79M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
BioDlink Announces New Corporate Logo, Affirms No Impact on Shareholder Rights or Operations
BioDlink International Co Ltd, formerly TOT BIOPHARM International Co Ltd, is a clinical-stage biopharmaceutical company principally engaged in developing and commercializing oncology drugs and therapies. The Company and its subsidiaries are primarily engaged in research, development, manufacturing, and marketing of anti-tumor drugs, contract development and manufacturing organization (CDMO) business and license-out of self-developed biological drugs in the People’s Republic of China. The Company owns a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The Company has built and established a fully integrated in-house platform of discovery, process development, quality management, pre-clinical and clinical development, as well as commercial-scale manufacturing facilities and sales and marketing capabilities. The Company mainly conducts its businesses in the domestic market.